Alessandro Laganà

Congrats!!

This review examines the key players driving MM, bridging basic science and clinical insights, and providing a roadmap for precision medicine. 🔬 #CancerGenomics

The Genetic and Molecular Drivers of Multiple Myeloma: Current Insight | PGPM We report key controversies and challenges in defining the genetic drivers of Multiple Myeloma, & examine their implications for future therapeutic strategies.

Thrilled to share our new review on the genomic and molecular drivers of #MultipleMyeloma! 🧬✨ We dive into the latest discoveries, their impact on disease progression, and how they inform therapeutic strategies. Check it out:
www.dovepress.com/articles.php...

Hello #ASH24! Come meet me tonight at the poster session: paper #4658 on immune features of myeloma subtypes.

Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma Key PointsRNA-seq analysis reveals a 6-gene signature that stratifies patients with MM by their predicted response to venetoclax.This study proposes a nove

The study here: ashpublications.org/bloodneoplas...

Our study bridges genomics and drug response, offering both predictive tools and a potential new strategy for patients resistant to venetoclax. #PrecisionMedicine #CancerResearch

1️⃣ Venetoclax works best for patients with t(11;14), but those with 1q gain are often resistant.
2️⃣ A six-gene signature helps predict response, providing a potential tool for precision medicine.
3️⃣ Excitingly, CDK7 inhibitors may help overcome resistance in patients with 1q gain.

Mount Sinai Researchers Identify Six-Gene Pattern to Predict Drug Success in Multiple Myeloma Patients

Excited to share our latest work in #MultipleMyeloma! 🧬 We uncovered a six-gene signature predicting response to venetoclax, but also revealed that 1q gain can drive resistance—and how CDK7 inhibitors might reverse it. #MyelomaResearch

Excited to connect with researchers and clinicians—always learning and looking to collaborate!

We focus on high-risk myeloma, integrating genomics and clinical data to develop AI-driven solutions for personalized treatment. #PrecisionMedicine

My lab studies the genomics and molecular drivers of multiple myeloma. Our mission? To uncover insights into treatment resistance and precision medicine using cutting-edge technologies like single-cell RNA-seq and spatial transcriptomics. 📍🗺️

Hello, Bluesky! 👋 Thrilled to join this space. I’m an Asst Prof working at the intersection of #CancerGenomics and computational biology, with a focus on high-risk #MultipleMyeloma. Looking forward to connecting with researchers, clinicians, and anyone passionate about advancing #MyelomaResearch! 🧬✨

Sky Follower Bridge - Chrome Web Store Instantly find and follow the same users from your Twitter follows on Bluesky.

It's Sky Follower Bridge:
chromewebstore.google.com/detail/sky-f...